Investigating new treatments for high-risk neuroblastoma using GPC2 CAR T cells
GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructs
['FUNDING_R37'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11015892
This study is looking at new ways to help children with high-risk neuroblastoma by using special immune cells that can better fight the cancer, and it aims to understand how the cancer can sometimes come back so that we can improve treatments and help kids live healthier lives.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11015892 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative therapies for children with high-risk neuroblastoma, a type of cancer that poses significant treatment challenges. The team is exploring the use of GPC2 chimeric antigen receptor (CAR) T cells, which are engineered to target a specific protein found on neuroblastoma cells. By understanding how these CAR T cells can be resisted by the cancer, the researchers aim to enhance their effectiveness and develop next-generation treatments. This work includes studying the mechanisms behind tumor relapse and finding ways to improve long-term outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with high-risk neuroblastoma.
Not a fit: Patients with neuroblastoma who are not classified as high-risk or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with high-risk neuroblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using CAR T cell therapies for various cancers, indicating a potential for success with this novel approach in neuroblastoma.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOSSE, KRISTOPHER R — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: BOSSE, KRISTOPHER R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy